Skip to content
Screener

Ligand Pharmaceuticals LGND Q1 2025 earnings

Reported May 8, 2025 · Before market open

Revenue$45.3MBeat by $1.0M
EPS$1.33Beat by $0.03
Revenue estimate$44.3M
EPS estimate$1.30

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$78.1M
EPS estimate$2.30

Financials

Q1 2025

Income statement

See full
Revenue$45.3M+46.3%
Operating income-$36.2M-1,312%
Net income-$42.5M-149%
EPS (diluted)-$2.21-147%

Balance sheet

See full
Cash & equivalents$48.0M-4.2%
Total debt$4.4M-28.2%
Total equity$795.6M-1.4%
Total assets$905.4M-0.9%

Cash flow

See full
Operating cash flow-$25.4M-236%
CapEx$214.0K+104%
Free cash flow-$25.7M-238%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$2.02B+56.4%
Enterprise value$1.98B+58.4%
P/S11.2×+0.2×

Profitability

See full
Operating margin-34.1%—
Net margin-73.1%-155pp
FCF margin28.1%-0.2pp

Returns & leverage

See full
Return on equity-16.6%-29.8pp
Debt / equity0×0.0×
Current ratio5.3×-15.4×

Segments

By product

See full
Qarziba$5.4M—
Filspari$5.3M+199%
Vaxneuvance$1.3M-7.4%

By segment

See full
Development and Licensing of Biopharmaceutical Assets$45.3M+46.3%

FAQ

When did Ligand Pharmaceuticals report Q1 2025 earnings?
Ligand Pharmaceuticals (LGND) reported Q1 2025 earnings on May 8, 2025 before market open.
What were Ligand Pharmaceuticals's Q1 2025 revenue and EPS?
Ligand Pharmaceuticals reported revenue of $45.3M and eps of $1.33 for Q1 2025.
Did Ligand Pharmaceuticals beat estimates in Q1 2025?
Revenue beat the consensus estimate of $44.3M by $1.0M. EPS beat the consensus estimate of $1.30 by $0.03.
How did Ligand Pharmaceuticals's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 46.3% from $31.0M a year earlier and eps grew 10.8% from $1.20.
Where can I find Ligand Pharmaceuticals's Q1 2025 SEC filings?
You can read the 8-K earnings release (0000886163-25-000033) and the 10-Q periodic report (0000886163-25-000036) directly on SEC EDGAR. The filing index links above go to sec.gov.